Novo Nordisk nears larger slice of type 2 diabetes market

30 May 2018

By beating a big rival in the space in a comparison study, Novo Nordisk’s (NOV: N) oral semaglutide has edged closer to gaining a larger share of the type 2 diabetes market.

The Danish drugmaker has announced the headline results from PIONEER 2, a Phase IIIa trial comparing the efficacy and safety of 14mg oral oral semaglutide compared with 25mg Jardiance (empagliflozin) in 816 people with type 2 diabetes, inadequately controlled on metformin.

Ozempic, the injectable form of the GLP-1 agonist, was approved late in 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK